← The Wire
ATAINasdaq
AtaiBeckley Inc.
Pharmaceutical Preparations · DE · CIK 2081043
AtaiBeckley Inc. develops psychedelic-based neuroplastogens for difficult-to-treat mental health conditions
$1.44B
Market cap
$5.36
Last close
+1.3%
1D
+32.4%
5D
10.6M
Volume
Price · last 39 sessions+27.6%
May 4L $3.78 · H $5.36Jun 29
14
Total filings
Jun 8, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 8, 20268-KReg FD DisclosureJun 3, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 20268-KMaterial AgreementMar 9, 20268-KCompany UpdateMar 6, 202610-K10-KMar 6, 20268-KResults of Operations · Reg FD DisclosureMar 6, 20268-KReg FD DisclosureFeb 26, 20268-KExecutive Change · Reg FD DisclosureFeb 19, 2026SC 13D/ASC 13D/AFeb 17, 20268-KExecutive Change · Reg FD DisclosureJan 8, 2026S-4S-4Sep 22, 2025
Insider Activity
In the 90 days to Mar 20, 2026: 2 sold $509K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 20, 2026 | Craig Kevin JamesChief Medical Officer | Sell | 100,000 | $3.55 | $355K |
| Jan 2, 2026 | Feilding-Mellen CosmoDirector | Sell | 39,594 | $3.90 | $154K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance